Skip to main content
SpringerLink
Log in

Systemische Progesterontherapie – transdermal?

Systemic progesterone therapy – transdermal?

  • Arzneimitteltherapie
  • Published:
Gynäkologische Endokrinologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Chabbert Buffet N, Djakoure C, Maitre SC, Bouchard P (1998) Regulation of the human menstrual cycle. Front Neuroendocrinol 19:151–186

    Article  Google Scholar 

  2. Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. Endocr Rev 18:502–519

    CAS  PubMed  Google Scholar 

  3. Bradbury JT, Brown WE (1951) Secretory and decidual changes induced in the endometrium of oophorectomized women by administration of estrogen and progesterone. J Clin Endocrinol Metab 11:267–276

  4. Challis JRG, Matthews SG, Gibb W, Lye SJ (2000) Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev 21:514–550

    CAS  PubMed  Google Scholar 

  5. Dey SK, Lim H, Das SK et al (2004) Molecular cues to implantation. Endocr Rev 25:341–343

    Article  CAS  PubMed  Google Scholar 

  6. Morville R, Dray F, Reynier J, Barrat J (1982) Biodisponibilité de la progestérone naturelle administrée par voie orale. Mesure des concentrations du stéroïde dans le plasma, l’endomêtre et le tissu mammaire. J Gynecol Obstet Biol Reprod 11:355–363

  7. Kleinstein J, Schlegelmilch R, Mazur D, Vens-Cappell B (2002) Vergleichende Pharmakokinetik von Progesteron-Kapseln und einem Progesteron-Gel nach vaginaler Anwendung. Arzneimittelforschung 52:615–621

    CAS  PubMed  Google Scholar 

  8. (o A) (1996) Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 275:370–375

  9. Pélissier C, Maroni M, Yaneva H et al (2001) Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. Maturitas 40:85–94

    Article  PubMed  Google Scholar 

  10. Santen RJ, Allred DC, Ardoin SP et al (2010) Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 95(7 Suppl 1):s1–s66

  11. Manson JE (2013) The Kronos Early Estrogen Prevention Study by Charlotte Barker. Womens Health (Lond Engl) 9:9–11

    Google Scholar 

  12. Gillet JY, Andre G, Faguer B et al (1994) Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas 19:103–115

    Article  CAS  PubMed  Google Scholar 

  13. Foidart JM, Dombrowicz D, Roelandt L et al (1993) Impact on the endometrium of hormone replacement with combined progesterone and percutaneous oestradiol. In: Christiansen C, Riis B (Hrsg) Proceedings of 4th International Symposium on Osteoporosis, Hong-Kong, 1993. Aalborg ApS, Dänemark, S 331–333

  14. Allen NE, Tsilidis KK, Key TJ et al (2010) Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 172:1394–1403

    Article  PubMed  Google Scholar 

  15. Santoro N (2005) The menopausal transition. Am J Med 118(Suppl 12B):8–13

    Article  PubMed  Google Scholar 

  16. Saarikoski DS, Yliskoski M, Penttila I (1990) Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas 12:89–97

    Article  CAS  PubMed  Google Scholar 

  17. Shangold MM, Zinaman MJ, Tomai TP et al (1991) Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril 56:1040–1047

    CAS  PubMed  Google Scholar 

  18. Nahoul K, Dehennin L, Jondet M, Roger M (1993) Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas 16:185–202

    Article  CAS  PubMed  Google Scholar 

  19. Levine H, Watson N (2000) Comparison of the pharmacokinetics of crinone 8 % administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril 73:516–521

    Article  CAS  PubMed  Google Scholar 

  20. Vaisbuch E, Ziegler D de, Leong M et al (2014) Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey. Reprod Biomed Online 28:330–335

    Article  PubMed  Google Scholar 

  21. Nonnenmacher A (2012) Progesteron zur Prävention der Frühgeburt. Gynäkologe 45:533–537

    Article  CAS  Google Scholar 

  22. Romero R, Nicolaides K, Conde-Agudelo A et al (2012) Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 206:124.e1–19

    PubMed Central  PubMed  Google Scholar 

  23. Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella (2012) Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 206:376–386

    Article  Google Scholar 

  24. Schleußner E (2013) Drohende Frühgeburt: Prävention, Diagnostik und Therapie. Dtsch Arztebl Int 110:227–236

    PubMed Central  PubMed  Google Scholar 

  25. Chang K-J, Lee TTY, Linares-Cruz G et al (1995) Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 63:785–791

    CAS  PubMed  Google Scholar 

  26. Foidart JM, Colin C, Denoo X et al (1998) Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 69:963–969

    Article  CAS  PubMed  Google Scholar 

  27. Sitruk-Ware R, Seradour B, Lafaye C (1980) Treatment of benign breast diseases by progesterone applied topically. In: Mauvais-Jarvis P, Vickers CHF (Hrsg) Percutaneous absorption of steroids. Academic Press, London New York, S 218–229

  28. Faust-Albrecht H (2013) Progesterontherapie transdermal – ein Erfahrungsbericht. Frauenarzt 54:44–50

    Google Scholar 

  29. Lewis JG, McGill H, Patton VM, Elder PA (2002) Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas 41:1–6

    Article  CAS  PubMed  Google Scholar 

  30. Vashisht A, Wadsworth F, Carey A et al (2005) A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. Gynecol Endocrinol 21:101–105

    Article  CAS  PubMed  Google Scholar 

  31. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96:1856–1865

  32. Benster B, Carey A, Wadsworth F et al (2009) A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause Int 15:63–69

    PubMed  Google Scholar 

  33. Stanczyk FZ, Paulson RJ, Roy S (2005) Percutaneous administration of progesterone: blood levels and endometrial protection. Menopause 12:232–237

    Article  PubMed  Google Scholar 

  34. Wren BG (2005) Transdermal progesterone creams for postmenopausal women: more hype than hope? Med J Austral 182:237–239

    PubMed  Google Scholar 

  35. O’Leary P, Feddema P, Chan K et al (2000) Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre- and postmenopausal women. Clin Endocrinol 53:615–620

    Article  Google Scholar 

  36. Du JY, Sanchez P, Kim L et al (2013) Percutaneous progesterone delivery via cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum, whole blood, saliva, and capillary blood. Menopause 20:1169–1175

    Article  PubMed  Google Scholar 

  37. Committee for Medicinal Products for Human use (CHMP) (2005) Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. EMEA/CHMP/021/97 Rev. 1, London

  38. Vashisht A, Wadsworth F, Carey A et al (2005) Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime. BJOG 112:1402–1406

    Article  CAS  PubMed  Google Scholar 

  39. Leonetti HB, Landes J, Steinberg D, Anasti JN (2005) Transdermal progesterone cream as an alternative progestin in hormone therapy. Altern Ther Health Med 11:36–38

    PubMed  Google Scholar 

  40. North American Menopause Society (2012) The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause 19:257–271

    Google Scholar 

  41. Schiff I (1982) The effects of progestins on vasomotor flushes. J Reprod Med 27:498–502

  42. Hitchcock CL, Prior JC (2012) Oral micronized progesterone for vasomotor symptoms – a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 19:886–893

    Article  PubMed  Google Scholar 

  43. Whelan AM, Jurgens TM, Trinacty M (2013) Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective? Ann Pharmacother 47:112–116

    Article  PubMed  Google Scholar 

  44. Leonetti HB, Longo S, Anasti JN (1999) Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 94:225–228

    Article  CAS  PubMed  Google Scholar 

  45. Wren BG, Champion SM, Willetts K et al (2003) Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 10:13–18

    PubMed  Google Scholar 

  46. US Department of Health and Human Services, US Food and Drug Administration (2003) Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms – recommendations for clinical evaluation

  47. Stephenson K, Neuenschwander PF, Kurdowska AK et al (2008) Transdermal progesterone: effects on menopausal symptoms and on thrombotic, anticoagulant, and inflammatory factors in postmenopausal women. Int J Pharmac Compounding 12:295–304

    Google Scholar 

  48. Benster B, Carey A, Wadsworth F et al (2009) Double-blind placebo-controlled study to evaluate the effect of pro-juven progesterone cream on atherosclerosis and bone density. Menopause Int 15:100–106

    PubMed  Google Scholar 

  49. Villiers TJ de, Pines A, Panay N et al (2013) Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16:316–337

    Article  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. A.O. Mueck gibt an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Bereiche Endokrinologie und Menopause, Universitäts-Frauenklinik und Forschungsinstitut für Frauengesundheit Tübingen, Calwer Str. 7, 72076, Tübingen, Deutschland

    A.O. Mueck

  2. OB/GYN Hospital, Capital Medical University Beijing, Beijing, China

    A.O. Mueck

Authors
  1. A.O. Mueck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A.O. Mueck.

Additional information

Modifiziert nach: Frauenarzt; 2014, 55(4)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mueck, A. Systemische Progesterontherapie – transdermal?. Gynäkologische Endokrinologie 13, 50–56 (2015). https://doi.org/10.1007/s10304-013-0571-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-013-0571-5

Search

Navigation